Zhong Guo Jing Ying Bao

Search documents
探路数据要素改革:地方如何形成数源集聚“强磁场”
Zhong Guo Jing Ying Bao· 2025-08-01 04:51
Core Insights - The article discusses the ongoing challenges in the data element industry, particularly the issues of "supply shortages and flow difficulties," and highlights the efforts being made to address these pain points through pilot projects initiated by the National Data Bureau [1][2] - Wenzhou has emerged as a leading pilot city, successfully implementing all six key tasks of the national data infrastructure pilot program, which includes the establishment of various data facilities [2][6] Group 1: Data Infrastructure Development - Wenzhou has launched six foundational infrastructure pilot projects, including trusted data spaces and data networks, which have begun to yield results [1][2] - The city has strategically positioned the data element industry as a key emerging sector, establishing the "Data Security Port" to enhance data safety and compliance [2][3] - The Data Security Port has attracted over 670 enterprises and developed more than 470 data products, showcasing its effectiveness in building a robust data ecosystem [2][3] Group 2: Institutional Innovation - The article emphasizes the need for a comprehensive data governance framework to address the challenges of data circulation, including compliance and security concerns [2][4] - Wenzhou has pioneered a full-process data governance system that includes pre-compliance review, technical safeguards, and post-judicial guarantees to facilitate data flow [3][4] - The establishment of a judicial support cluster, including a data resource court and arbitration center, provides essential legal and compliance certainty for data transactions [3][4] Group 3: Future Development and Collaboration - Wenzhou aims to deepen the integration of data elements with the real economy, focusing on creating high-value application scenarios to drive infrastructure capabilities [6][7] - The city plans to expand its influence by attracting leading enterprises and establishing national-level laboratories to enhance data resource aggregation [7] - A collaborative initiative called the "Hundred Cities Action" has been launched, involving 25 cities to promote data product development, infrastructure connectivity, and digital reform applications [7]
视频|完美世界集团高级副总裁伊迪金句
Zhong Guo Jing Ying Bao· 2025-08-01 03:39
0:00 完美世界集团高级副总裁伊迪:文化出海近几年屡屡被提及,这个背后我觉得有三个"力"发挥作用:第 一,产业的"硬实力"。第二,文化"自信力"。第三,用户的"共情力"。 ...
视频 世纪华通董事会秘书、副总裁黄怡金句
Zhong Guo Jing Ying Bao· 2025-08-01 03:39
世纪华通董事会秘书、副总裁黄怡:为什么出海游戏做得这么好?第一,充分了解国外客户的消费习惯 和偏好。第二,要抓住国外游戏行业的变化趋势。第三,要更加的考验团队的专注度,并且找到自己独 特的定位,一直坚持下去。 0:00 ...
科创板第五套上市标准重启后首家!上交所受理泰诺麦博IPO申请
Zhong Guo Jing Ying Bao· 2025-08-01 03:18
最近三年,公司研发投入超过11亿元。公司搭建了"高通量全人源单克隆抗体研发综合技术平台 HitmAb®""高效抗体表达CHO-GS细胞平台"等多项核心技术平台,不断培养健全涵盖药物发现、工程 细胞株构建、工艺及质量开发、药理研究、毒理研究、药代研究、临床开发以及符合国际GMP规范的 规模化生产等关键药物研发与产业化环节的创新药核心技术能力。 公司核心在研产品TNM001,是潜在的全球第三、我国首款适用于健康及高危婴幼儿的预防用长效抗 RSV单抗药物,目前已进入III期临床试验阶段。此外,公司在镇痛(TNM009)、预防水痘-带状疱疹 (TNM005)、预防人巨细胞病毒(TNM006)等领域均有布局。 (编辑:夏欣 审核:何莎莎 校对:颜京宁) 分析人士认为,泰诺麦博以第五套标准申报科创板获受理,系证监会"1+6"新政公布后"科创-资本"双循 环的崭新落地实践,亦标志着上交所科创板进一步充分发挥服务未盈利科创企业的积极作用,科创板正 从改革"试验田"迈向科创"新高地"。 根据《上海证券交易所发行上市审核规则适用指引第8号——资深专业机构投资者》的相关规定,泰诺 麦博认定珠海高瓴私募基金管理有限公司(以下简称"珠 ...
视频 丨 云迹科技副总裁 谢云鹏金句
Zhong Guo Jing Ying Bao· 2025-08-01 02:46
云迹科技副总裁 谢云鹏:AI本身并不具有强产业属性,它要融入到产业当中去看到底怎么才能产生技 术的价值,到底如何满足需求的,这个是使用AI最核心的理念。 0:00 ...
上半年国内游戏市场收入1680亿元 同比增长14.08%
Zhong Guo Jing Ying Bao· 2025-07-31 17:37
中国音像与数字出版常务副理事长兼秘书长敖然表示:"游戏经济正呈现出显著的涟漪效应:游戏产业 自身持续增长,带动文化产业加速发展,并促进文化向更广泛的外部领域持续赋能。这种涟漪效应可以 划分为三个相互关联的价值圈层:对自身发展的核心价值、对文化产业的驱动价值、对多元外部领域的 外溢价值。" 收入再创新高 《报告》统计数据显示,2025年上半年,国内游戏市场实际销售收入1680亿元,同比增长14.08%,再 创新高。游戏用户规模近6.79亿户,同比增长0.72%,亦为历史新高点。 这主要得益于多种因素影响。一是多款游戏新品上市后表现不凡,超出预期;二是多款长青游戏运营良 好,收入稳中有升;三是电子竞技和小程序游戏增长势头强劲。 中经记者李哲上海报道 7月31日,中国国际数字娱乐产业大会(CDEC)在上海召开。会上对外发布的《2025年1—6月中国游 戏产业报告》(以下简称"《报告》")显示,上半年我国游戏市场销售收入同比增长14.08%,再创新 高。 具体来看,凭借多款热门长青产品和新作的出色表现,上半年自研游戏国内市场实际销售收入1404.52 亿元,同比增长19.29%;海外市场实际销售收入95.01亿美元, ...
北京强降雨30余万人受灾,太师屯镇养老中心“预案没有将其列入转移范围”
Zhong Guo Jing Ying Bao· 2025-07-31 17:34
余卫国介绍,28日清晨,洪水冲进街道,整条街迅速被淹没,最深处达2米。接到报警后,消防救援力 量迅速出动,7时左右抵达照料中心附近,但因水流湍急,救援力量难以进入。经过多方努力,10时许 陆续救出被困人员,搜救工作一直持续到第二天,其间陆续发现多名老人不幸罹难。 "汛期前,我们按照工作预案,根据天气预警情况,提前对险村险户统计台账上的群众进行避险转移, 全区共转移205个村1.6万余人。"余卫国说,长期以来,这个养老中心所在镇中心区域都是安全的,预 案没有将其列入转移范围。"这说明我们的预案是有漏洞的,我们对于极端天气的认识是不足的。" 中经记者封莉北京报道 据了解,密云区受灾最重的太师屯镇,上游的干峪沟12小时降雨量达到290.7毫米(特大暴雨级别), 同时清水河水位暴涨,降雨、山洪、河流洪水叠加。28日清晨,清水河流量骤增,最大流量达每秒2800 立方米,是平时流量的1500倍,迅猛的来水进入太师屯镇区,造成巨大灾害。 7月31日,《中国经营报》记者从北京市防汛救灾新闻发布会上获悉,截至7月31日12时,北京此轮强降 雨因灾死亡44人,失踪失联9人。其中,密云太师屯镇养老照料中心死亡31人,失踪失联人员中 ...
Surge AI估值超千亿元 数据标注产业走向台前
Zhong Guo Jing Ying Bao· 2025-07-31 17:32
Core Insights - Surge AI has rapidly become a prominent player in the AI sector, achieving a valuation of $15 billion and seeking $1 billion in its first funding round [1] - The company exemplifies the data labeling industry, which is crucial for the development of high-quality datasets necessary for AI [1][2] - Surge AI's growth is significantly driven by the increasing demand for AI data, which is growing at an exponential rate of 230% annually [2] Company Overview - Founded in 2020 by Edwin Chen, a former engineer at Google and Meta, Surge AI aims to address inefficiencies in traditional data labeling [2] - The company achieved eight-digit revenue within its first year and is projected to surpass $1 billion in revenue by 2024 [3] - Surge AI collaborates with major tech firms like OpenAI, Google, and Microsoft, enhancing the performance of large language models through quality grading and verification [3] Industry Trends - The data labeling market in China is expected to grow from approximately 3 billion yuan in 2020 to around 8 billion yuan by 2024, with a compound annual growth rate exceeding 25% [6] - The industry is witnessing a shift from manual labor to human-machine collaboration, with increasing penetration of AI-assisted tools [1][6] - The Chinese government is supporting the data labeling industry through policies and the establishment of data labeling bases in several cities [7] Future Directions - The data labeling industry is expected to evolve towards three main breakthroughs: active learning frameworks, cross-modal joint labeling, and privacy computing integration [8] - There is a growing need for intelligent labeling solutions that utilize deep learning and reinforcement learning to automate and enhance data labeling processes [8]
徐强:人工智能正在进入地域分工时代
Zhong Guo Jing Ying Bao· 2025-07-31 17:30
"我们在做一个有关区域经济与人工智能发展的研究。一个地方计划发展人工智能时,要避免'人有多大 胆,地有多大产'的盲目扩张。"7月30日,国家信息中心党委书记、主任徐强在一场经济领域研讨会上 表示。 他指出,一个地方发展人工智能,应该了解这个地方是否在算力方面有优势,或者在数据方面有优势、 在应用场景方面有优势,这些问题必须深刻分析。 他表示,发展人工智能要实事求是、因地制宜。不同地区、技术、产业的发展规律各异,需立足实际。 例如,中部或西部地区可能在算力领域具备优势,而算法研究、技术创新更依赖上海、北京、杭州、深 圳等人才集聚地。 中国现在已经成为新质生产力发展最重要、最活跃的试验场。徐强分享了近期参与上海"第七届世界人 工智能大会"的见闻:展会现场人潮涌动,几乎无法顺畅通行。 "我看到一些报道,原本168元/张的市民门票被炒至2000元。"他表示,这侧面印证了人工智能已从"实 验室""象牙塔"走向大众生活,各类企业针对不同应用场景已推出成熟成果。他强调,人工智能技术更 新极快。 徐强认为,人工智能正从算法智能向感知智能跨越(当前感知智能已较成熟),下一步将迈向认知智 能,新质生产力已成为发展战略性新兴产业、 ...
外资药企涉嫌接受虚开发票3亿元 被处罚30万元
Zhong Guo Jing Ying Bao· 2025-07-31 16:56
Core Viewpoint - Jiangsu Qianshou Pharmaceutical Co., Ltd., a subsidiary of a well-known foreign pharmaceutical company, is involved in a scandal regarding the issuance of false invoices amounting to 309 million yuan [1][3]. Group 1: Invoice Fraud Details - From December 2019 to August 2021, Jiangsu Qianshou Pharmaceutical received 2,022 VAT invoices from 37 individual businesses, totaling 195 million yuan [1][3]. - Between November 2022 and October 2023, the company accepted 603 VAT invoices from 13 enterprises, amounting to 114 million yuan [2][3]. - The total amount of the fraudulent invoices is 309 million yuan [3]. Group 2: Administrative Penalties - The tax authority imposed a fine of 300,000 yuan on Jiangsu Qianshou Pharmaceutical for its involvement in the issuance of false invoices [1][4]. - The administrative penalty decision indicated that the company engaged in invoice exchanges without corresponding financial transactions, suggesting the acceptance of false invoices [4]. Group 3: Company Background - Jiangsu Qianshou Pharmaceutical was established in February 2018 and primarily engages in the wholesale and import-export of pharmaceuticals and medical devices [4]. - It is a wholly-owned subsidiary of Japan's Qianshou Pharmaceutical Co., Ltd., a well-known multinational company specializing in ophthalmic drug research and production since 1947 [4][5].